Type II CRISPR/Cas9 approach in the oncological therapy
Crossref DOI link: https://doi.org/10.1186/s13046-017-0550-0
Published Online: 2017-06-15
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Biagioni, A. http://orcid.org/0000-0002-6193-7417
ChillĂ , A.
Andreucci, E.
Laurenzana, A.
Margheri, F.
Peppicelli, S.
Del Rosso, M.
Fibbi, G.